Detail akcie GSK ADS-WI online

Business Summary: GSK plc is a United Kingdom-based biopharma company. The Company is focused on the science of the immune system and advanced technologies, investing in four core therapeutic areas-respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its segments include Commercial Operations and Research and Development. Its specialty medicines prevent and treat diseases, from asthma, cancer and HIV to autoimmune diseases like lupus. General medicines include inhalers for asthma and chronic obstructive pulmonary disease (COPD) to antibiotics. It also owns ozureprubart, a long-acting anti-immunoglobulin E (IgE) monoclonal antibody and HS235, a potential molecule for the treatment of pulmonary hypertension (PH). Its oncology portfolio also includes Zidesamtinib (NVL-520), neladalkib (NVL-655), and NVL-330. Its products include Anoro Ellipta, Apretude, Arexvy, Bexsero, Blenrep, Blujepa, Boostrix, Cervarix, Dovato, Efimosfermin, among others.
Financial Summary: BRIEF: For the six months ended 30 June 2026, GSK plc (ADR) revenues increased 3% to L16.04B. Net income decreased 29% to L2.17B. Revenues reflect Europe segment increase of 15% to L4.13B, US segment increase of 2% to L8.05B. Net income was offset by Other segment loss increase from L925M to L2.68B, Unallocated segment loss increase from L42M to L228M, Research and Development segment loss increase of 6% to L2.99B.